ESTEVE Expands Portfolio with Acquisition of Caprelsa® to Treat Medullary Thyroid Cancer

ESTEVE Expands Portfolio with Caprelsa® Acquisition



In a significant move to enhance its specialized treatment offerings, ESTEVE has finalized an agreement with Sanofi to acquire the rights to Caprelsa® (vandetanib) for over 50 countries. This medication is pivotal for both adults and children aged five and above suffering from aggressive and symptomatic medullary thyroid cancer, a rare but serious condition that requires highly focused medical interventions.

Understanding Medullary Thyroid Cancer


Medullary thyroid carcinoma originates in the thyroid gland's C-cells, which produce calcitonin. As a protein tyrosine kinase inhibitor, Caprelsa® functions by inhibiting the activity of specific enzymes known as tyrosine kinases. By doing so, it disrupts the blood supply to cancer cells, effectively slowing their growth and progression.

José María Giménez-Arnau, Chief Scientific Medical Officer at ESTEVE, emphasizes the importance of Caprelsa® in supporting patients diagnosed with this challenging disease. He states, "The primary means to address medullary thyroid carcinoma is surgery. However, treatments like vandetanib can be instrumental in halting or even partially reversing tumor advancement. Our aim is to stand alongside patients and healthcare professionals in this fight against cancer."

ESTEVE's Strategic Growth


This acquisition marks yet another step in ESTEVE's journey to international growth and specialization in treatment for high unmet medical needs. Previously, in April 2024, the company enhanced its portfolio by acquiring a business focused on rare diseases related to endocrinology and onco-endocrinology, introducing three new medicines aimed at addressing conditions such as endogenous Cushing's syndrome and adrenocortical carcinoma.

Moreover, just last month, ESTEVE secured licenses for innovative biologic therapies designed for children suffering from severe primary insulin-like growth factor-1 deficiency, alongside a standard treatment for high-grade osteosarcoma in young patients. Jacob Tolstrup, Chief Commercial Officer, stated, "We are thrilled to expand our highly specialized therapies portfolio. Caprelsa® represents a critical addition that will significantly impact patients' lives on a global scale."

Regulatory Considerations


The completion of the transaction hinges on securing customary regulatory approvals, a typical procedure in pharmaceutical acquisitions, ensuring that all safety and efficacy standards are met.

About ESTEVE


Founded in 1929 and headquartered in Barcelona, ESTEVE is committed to improving people's lives through innovative pharmaceutical solutions. With a strong international presence and a dedication to addressing significant unmet medical needs across various therapeutic areas, ESTEVE manages to integrate both cutting-edge treatment development and comprehensive contract manufacturing services.

For further inquiries, Irene Simón, Head of Global External Communications at ESTEVE, is available at +34 934 466 000.

In this rapidly evolving market, ESTEVE's focus on specialized treatments reflects a broader commitment within the healthcare sector to tackle complex medical challenges, ensuring improved health outcomes for patients worldwide.

This strategic acquisition of Caprelsa® marks a pivotal moment for ESTEVE, reinforcing their position as a key player in delivering effective therapies for rare and aggressive conditions.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.